uniQure (NASDAQ:QURE) Stock Rating Reaffirmed by Chardan Capital

uniQure (NASDAQ:QURE – Get Rating)‘s stock had its “buy” rating reaffirmed by investment analysts at Chardan Capital in a report released on Tuesday, Zacks.com reports. A number of other analysts have also weighed in on the stock. UBS Group raised shares of uniQure from a “neutral” rating to a “buy” rating and set a $40.00 […]

Related Keywords

Alexander Edward Kuta ,Matthewc Kapusta ,Raymond James ,Capital Management ,Zacks Investment Research ,Blackrock Inc ,Privium Fund Management United Kingdom Ltd ,Qure Company Profile Get Rating ,Nasdaq ,Get Rating ,Chardan Capital ,Fund Management United Kingdom Ltd ,State Street Corp ,Street Corp ,Qure Company Profile ,Uniqure ,Nasdaq Qure ,Qure ,Medical ,Reiterated Rating ,